Bendell, Johanna C.Sauri, TamaraGracian, Antonio CubilloAlvarez, RafaelLopez-Lopez, CarolsGarcia-Alfonso, PilarHussein, MaenLimon Miron, Maria-LuisaCervantes, AndresMontagut, ClaraSantos Vivas, CristinaBessudo, AlbertoPlezia, PatricaMoons, VeerleAndel, JohannesBennouna, Jafaarvan der Westhuizen, AndreSamuel, LeslieRossomanno, SimonaBoetsch, ChristopheLahr, AngelikaFranjkovic, IzoldaHeil, FlorianLechner, KatharinaKrieter, OliverHurwitz, Herbert2020-03-172020-03-172020-03Bendell, J C, Sauri, T, Gracian, A C, Alvarez, R, Lopez-Lopez, C, Garcia-Alfonso, P, Hussein, M, Limon Miron, M-L, Cervantes, A, Montagut, C, Santos Vivas, C, Bessudo, A, Plezia, P, Moons, V, Andel, J, Bennouna, J, van der Westhuizen, A, Samuel, L, Rossomanno, S, Boetsch, C, Lahr, A, Franjkovic, I, Heil, F, Lechner, K, Krieter, O & Hurwitz, H 2020, 'The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)', Oncologist, vol. 25, no. 3, pp. e451-e459. https://doi.org/10.1634/theoncologist.2019-02911083-7159ORCID: /0000-0002-8402-8670/work/79064869https://hdl.handle.net/2164/13875We thank the patients and their families for their participation in this study and the staff at the study sites. This study and editorial support for the preparation of this manuscript were funded by F. Hoffmann-La Roche Ltd. Support for third-party writing assistance for this article, furnished by Goran Westerburg, Ph.D., was provided by La Crocina Pharmaceutical Consultants Lp.91033773engSDG 3 - Good Health and Well-beingFirst-line metastatic colorectal cancerAngiopoetin-2VEGF-AVanucizumabBevacizumabBIOMARKERANTIBODYPHASE-IIOXALIPLATINANGIOPOIETIN-2ANTITUMOR-ACTIVITYCOMBINATIONHYPERTENSIONAMG 386CLINICAL-OUTCOMESR MedicineOncologyCancer ResearchSupplementary DataRJournal article10.1634/theoncologist.2019-0291http://www.scopus.com/inward/record.url?scp=85074443333&partnerID=8YFLogxK253